ApollomicsAPLM
Market Cap: 24.4M
About: Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Employees: 45
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0.44% more ownership
Funds ownership: 9.89% [Q4 2023] → 10.33% (+0.44%) [Q1 2024]
8% less funds holding
Funds holding: 13 [Q4 2023] → 12 (-1) [Q1 2024]
19% less capital invested
Capital invested by funds: $8.54M [Q4 2023] → $6.94M (-$1.6M) [Q1 2024]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
HC Wainwright & Co. Robert Burns | 801%upside $2 | Buy Maintained | 8 May 2024 |
EF Hutton Michael King | 2,828%upside $6.5 | Buy Maintained | 1 Apr 2024 |
HC Wainwright & Co. Robert Burns | 2,152%upside $5 | Buy Maintained | 1 Apr 2024 |